Skip to main content
. 2020 Feb 27;43(1):53–61. doi: 10.1016/j.bj.2019.05.010

Table 4.

Characteristics of the PTC-with-HPT group: non-remission and mortality.

Characteristic Non-remission (n = 3) Mortality (n = 4)
Age at diagnosis, sex 53, F 31, M 54, M 44, F 65, F 61, F 63, F
Pathology of PTC C C C C C C FV
Multifocality no yes yes no no no no
Tumor size (cm), stage 0.2, T1A 1.0, T1A 4.0, T4A 2.4, T4A 0.4, T1A 1.5, T1B 1.4, T1B
Lymph nodes status N0 N1A N1A N0 N0 N0 N0
TNM stage SI SI SVIa SI SI SI SI
Total thyroidectomy yes yes yes yes no no yes
1M-Post-op Tg (ng/mL) 13.8 512 63.6 2.95 64.2 13.7
Post-op131I dose (mCi) 100.0 420.0 490.0 29.8 30.0
Time-to-event (year) 0.7 10.8 6.9 8.5 4.3 4.2 4.5
Location or death cause neck, lung neck neck stroke unknown unknown ALI
Second primary cancer no RCC, HCC no no TCC no no
Etiology of HPT primary renal primary renal renal renal renal

F, female; M, male; C, classic; FV, follicular variant; 1M-Post-op Tg, one-month postoperative serum thyroglobulin level; Post-op 131I dose, postoperative 131I cumulative dose; ALI, acute limb ischemia; RCC, renal cell carcinoma; HCC, hepatocellular carcinoma; TCC, transitional cell carcinoma.